BioTuesdays

Tag - NLTX

Neurogene-Logo
Developments

Neurogene and Neoleukin in merger accord

Close-held Neurogene and Neoleukin Therapeutics (NASDAQ:NLTX) entered into a definitive merger agreement to combine the companies in an all-stock transaction. The combined company will focus on advancing Neurogene’s...

July 18, 2023
Neoleukin-Therapeutics
Markets

Stifel starts Neoleukin Therapeutics at buy; PT $18

Stifel launched coverage of Neoleukin Therapeutics (NASDAQ:NLTX) with a “buy” rating and $18 price target. The stock closed at $14.61 on Jan. 5. Neoleukin is creating next generation immunotherapies primarily for...

January 6, 2021